BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dingemanse J, Hoever P. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects. Drugs R D 2013;13:145-51. [PMID: 23737453 DOI: 10.1007/s40268-013-0017-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Weiss D, Knight R, Zhou S, Palmisano M, Chen N. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting. Clin Drug Investig 2015;35:455-61. [PMID: 26024727 DOI: 10.1007/s40261-015-0299-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bruderer S, Okubo K, Mukai H, Mant T, Dingemanse J. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. Clinical Therapeutics 2016;38:1228-1236.e1. [DOI: 10.1016/j.clinthera.2016.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
3 Maass C, Stokes CL, Griffith LG, Cirit M. Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS). Integr Biol (Camb) 2017;9:290-302. [PMID: 28267162 DOI: 10.1039/c6ib00243a] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 8.4] [Reference Citation Analysis]